Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.
Oncolytics Biotech Stock Performance
The stock has a fifty day moving average of C$14.90 and a 200-day moving average of C$14.90. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
